In vitro generation of bacillus Calmette-Gueérin-activated killer cells

Clinical Infectious Diseases

Volumn 31, Issue , 2000, Pages S94-S100

  Brandau, S ^a   Bohle A ^b   Thanhauser A ^a   Ernst, M ^a   Mattern, T ^a   Ulmer, A J ^a   Flad, H D ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; KILLER CELL; LYMPHOKINE ACTIVATED KILLER CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL;

BCG VACCINE; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0034453060     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314068     Document Type: Article

References (24)

1. Presence of activated lymphocytes in the urine of patients after intravesical immunotherapy with bacillus Calmette-Guérin
2. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall
3. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy
4. Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical bacillus Calmette-Guérin
5. Radioimmunoassay detection of interferon-γ in urine after intravesical Evans BCG therapy
6. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines
7. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines
8. Antibody response in rabbits to immunization with Mycobacterium leprae
9. Phenotypical and functional characterization of FC receptor I (CG64)-negative monocytes, a minor human monocyte population with high accessory and antiviral activity
10. A rapid method for the isolation of functional thymus-derived murine lymphocytes
11. Dissociation of responses measured by natural cytotoxicity and chemiluminescence
12. Density dependent tumor cell death and reversible cell cycle arrest: Mutually exclusive modes of monocyte mediated growth control
13. 75Se-release: A short- and long-term assay system for cellular cytotoxicity
14. Lymphokine-activated killer cell phenomenon: Lysis of natural-killer cell resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes
15. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity
16. Induction of bacillus Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro
17. Lymphokine activated killer cells: Analysis of progenitors and effectors
18. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes
19. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer with interleukin-2
20. Human γδ T cells respond to mycobacterial heat-shock protein
21. The induction of bacillus Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells
22. Induction of urinary interleukin-1 (IL- 1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer
23. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy
24. T cell subsets required for intravesical BCG immunotherapy for bladder cancer